{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:29:48Z","timestamp":1788492588837,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA224696"],"award-info":[{"award-number":["R01CA224696"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.steroids.2022.109062","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T11:28:25Z","timestamp":1654687705000},"page":"109062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Large-scale synthesis of galeterone and lead next generation galeterone analog VNPP433-3\u03b2"],"prefix":"10.1016","volume":"185","author":[{"given":"Puranik","family":"Purushottamachar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Retheesh S.","family":"Thankan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Rudchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2630-8479","authenticated-orcid":false,"given":"Vincent C.O.","family":"Njar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.steroids.2022.109062_b0005","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1021\/jm040202w","article-title":"Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model","volume":"48","author":"Handratta","year":"2005","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.steroids.2022.109062_b0010","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/jm501239f","article-title":"Discovery and development of Galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer","volume":"58","author":"Njar","year":"2015","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.steroids.2022.109062_b0015","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1021\/acs.oprd.6b00217","article-title":"Improved Procedures for Gram-Scale Synthesis of Galeterone 3\u03b2-Imidazole and Galeterone 3\u03b2-Pyridine Methoxylate, Potent Androgen Receptor\/Mnk Degrading Agents","volume":"20","author":"Purushottamachar","year":"2016","journal-title":"Org. Process Res. Dev."},{"issue":"7","key":"10.1016\/j.steroids.2022.109062_b0020","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/acsmedchemlett.6b00137","article-title":"Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3\u03b2-Imidazole Carbamate","volume":"7","author":"Purushottamachar","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2022.109062_b0025","doi-asserted-by":"crossref","unstructured":"A.K. Kwegyir-Afful, S. Ramalingam, V.P. Ramamurthy, P. Purushottamachar, F.N. Murigi, T.S. Vasaitis, W. Huang, M.A. Kane, Y. Zhang, N. Ambulos, S. Tiwari, P. Srivastava, I.P. Nnane, A. Hussain, Y. Qiu, D.J. Weber, V.C.O. Njar, Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3beta Exert Potent Therapeutic Effects in Castration-\/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo, Cancers (Basel) 11(11) (2019).","DOI":"10.3390\/cancers11111637"},{"issue":"3","key":"10.1016\/j.steroids.2022.109062_b0030","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1021\/ol802343z","article-title":"Practical synthesis of 3beta-amino-5-cholestene and related 3beta-halides involving i-steroid and retro-i-steroid rearrangements","volume":"11","author":"Sun","year":"2009","journal-title":"Org. Lett."},{"issue":"12","key":"10.1016\/j.steroids.2022.109062_b0035","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1021\/jm400048v","article-title":"Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer","volume":"56","author":"Purushottamachar","year":"2013","journal-title":"J. Med. Chem."},{"issue":"114441","key":"10.1016\/j.steroids.2022.109062_b0040","first-page":"1","article-title":"Novel deuterated Mnk1\/2 protein degrader VNLG-152R analogs: Synthesis, In vitro Anti-TNBC activities and pharmacokinetics in mice","volume":"238","author":"Purushottamachar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2022.109062_b0045","doi-asserted-by":"crossref","first-page":"34653","DOI":"10.1038\/srep34653","article-title":"A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells","volume":"6","author":"Thomas","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.steroids.2022.109062_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/mc.23406","article-title":"Transcriptome profiling reveals that VNPP433-3beta, the lead next-generation galeterone analog inhibits prostate cancer stem cells by downregulating epithelial-mesenchymal transition and stem cell markers","author":"Thomas","year":"2022","journal-title":"Mol. Carcinog."},{"issue":"12 Suppl.","key":"10.1016\/j.steroids.2022.109062_b0055","article-title":"Mechanistic insights on the effects of the lead next generation galeterone analog, VNPP433-3\u03b2 in castration resistant prostate cancer","volume":"20","author":"Thomas","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.steroids.2022.109062_b0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17518250903258150","article-title":"Green process chemistry in the pharmaceutical industry","volume":"2","author":"Cue","year":"2009","journal-title":"Green Chem. Lett. Rev."},{"issue":"3","key":"10.1016\/j.steroids.2022.109062_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/jpri\/2019\/v28i330203","article-title":"An Overview on Common Organic Solvents and Their Toxicity","volume":"28","author":"Joshi","year":"2019","journal-title":"J. Pharm. Res. Int."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X22001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X22001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:09:15Z","timestamp":1758535755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X22001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":13,"alternative-id":["S0039128X22001003"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2022.109062","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Large-scale synthesis of galeterone and lead next generation galeterone analog VNPP433-3\u03b2","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2022.109062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109062"}}